Page 2523 - Hematology_ Basic Principles and Practice ( PDFDrive )

2246 Part XIII Consultative Hematology

12. Eschbach JW, Cook JD, Scribner BH, et al: Iron balance in hemodialysis 28. Zwaginga JJ, Koomans HA, Sixma JJ, et al: Thrombus formation and
patients. Ann Intern Med 87(6):710–713, 1977. platelet vessel wall interaction in the nephrotic syndrome under flow
13. Benigni A, Boccardo P, Galbusero M, et al: Reversible activation defect conditions. J Clin Invest 93(1):204–211, 1994.
of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am 29. Yoshida N, Aoki N: Release of arachidonic acid from human platelets. A
J Kidney Dis 22(5):668–676, 1993. key role for the potentiation of platelet aggregability in normal subjects
14. Horowitz HI, Stein IM, Cohen BD: Further studies on the platelet as well as those with nephrotic syndrome. Blood 52(5):969–977, 1978.
inhibitory effect of guanidinosuccinic acid and its role in uremic bleed- 30. Vaziri ND, Ngo JL, Ibsen KH, et al: Deficiency and urinary losses of
ing. Am J Med 49(3):336–345, 1970. factor XII in adult nephrotic syndrome. Nephron 32(4):342–346, 1982.
15. Remuzzi G, Perico B, Zoja C, et al: Role of endothelium-derived nitric 31. Kauffman RH, Veltkamp JJ, Van Tilburg NH, et al: Acquired antithrom-
oxide in the bleeding tendency of uremia. J Clin Invest 86(5):1768–1771, bin III deficiency and thrombosis in the nephrotic syndrome. Am J Med
1990. 65(4):607–613, 1978.
16. Livio M, Gotti E, Marchesi D, et al: Uremic bleeding: role of anemia 32. Vigano-D’angelo S, D’angelo A, Kaufman CE, et al: Protein S deficiency
and beneficial effect of red cell transfusions. Lancet 2(8306):1013–1015, occurs in the nephrotic syndrome. Ann Intern Med 107(1):42–47, 1987.
1982. 33. Vaziri ND, Branson HE, Ness R: Changes of coagulation factors IX, VIII,
17. Zeigler ZR, Megaludis A, Fraley DS: Desmopressin (d-DAVP) effects VII, X and V in nephrotic syndrome. Am J Med Sci 280(3):167–171,
on platelet rheology and von willebrand factor activities in uremia. 1980.
Am J Hematol 39(2):90–95, 1992. 34. De Sain-van der Velden MG, Kaysen GA, de Meer K, et al: Proportion-
18. Livio M, Manucci PM, Vigano G, et al: Conjugated estrogens for the ate increase of fibrinogen and albumin synthesis in nephrotic patients:
management of bleeding associated with renal failure. N Engl J Med measurements with stable isotropes. Kidney Int 53(1):181–188, 1998.
315(12):731–735, 1986. 35. Singhal R, Brimble KS: Thromboembolic complications in the nephrotic
19. Zoja C, Noris M, Corna D, et al: L-arginine, the precursor of nitric syndrome: pathophysiology and clinical management. Thromb Res
oxide, abolishes the effect of estrogens in bleeding time in experimenta 118(3):397–407, 2006.
uremia. Lab Invest 65(4):479–483, 1991. 36. Rabelink TJ, Zwaginga JJ, Koomans HA, et al: Thombosis and hemo-
20. Livio M, Gotti E, Marchesi D, et al: Uraemic bleeding: role of anaemia stasis in renal disease. Kidney Int 46(2):287–296, 1994.
and beneficial effect of red cell transfusions. Lancet 2(8306):1013–1015, 37. Glassock RJ: Prophylactic anticoagulation in nephrotic syndrome: a
1982. clinical conundrum. JASN 18(8):2221–2225, 2007.
21. Cases A, Escolar G, Reverter JC, et al: Recombinant human erythropoi- 37a. Vilchez JA, Gallego P, Lip GYH: Safety of new oral anticoagulant drugs:
etin treatment improves platelet function in uremic patients. Kidney Int a perspective. Ther Adv Drug Saf 5(1):8–20, 2014.
42(3):668–672, 1992. 38. Capodanno D, Angiolillo DJ: Antithrombotic therapy in patients with
22. Nenci GG, Berrettini M, Agnelli G, et al: Effect of peritoneal dialysis, chronic kidney disease. Circulation 125:2649–2661, 2012.
haemodialysis and kidney transplantation on blood platelet function. 39. Barbour T, Johnson S, Cohney S, et al: Thrombotic microangiopathy
Nephron 23(6):287–292, 1979. and associated renal disorders. Nephrol Dial Transplant 27(7):2673–2685,
23. Orth SR, Ritz E: The nephrotic syndrome. N Engl J Med 338:1202–1211, 2012.
1998. 40. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy,
24. Mahmoodi BK, Ten Kate MK, Waanders F, et al: High absolute risk hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.
and predictors of venous and arterial thromboembolic events in patients Kidney Int 60(3):831–846, 2001.
with nephrotic syndrome: results from a large retrospective cohort study. 41. Kose O, Zimmerhackl LB, Jungraithmayr T, et al: New treatment
Circulation 117(2):224–230, 2008. options for atypical hemolytic uremic syndrome with complement
25. Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al: A population based inhibitor eculizumab. Semin Thomb Hemost 36(6):669–672, 2010.
perspective of the hospital incidence and case fatality rates of deep vein 42. Taylor AL, Marcus R, Bradley JA: Post transplant lymphoproliferative
thrombosis and pulmonary embolism. The Worcester DVT study. Arch disorders (PTLD) after solid organ transplantation. Crit Rev Oncol
Int Med 151(5):933–938, 1991. Hematol 56(1):155–167, 2005.
26. Lionaki S, Derebail VK, Hogan SL, et al: Venous thromboembolism 43. Caillard S, Dharnidarka V, Agodoa L, et al: Posttransplant lymphoprolif-
in patients with membranous nephropathy. Clin J Am Soc Nephrol erative disorders after renal transplantation in the United States in era of
7(1):43–51, 2012. modern immunosuppression. Transplantation 80(9):1233–1243, 2005.
27. Barbour SJ, Greenwald A, Djurdjev O, et al: Disease-specific risk of 44. Vlahakos DV, Marathias KP, Agroyannis B, et al: Posttransplant eryth-
venous thromboembolic events is increased in idiopathic glomerulone- rocytosis. Kidney Int 63(4):1187, 2003.
phritis. Kidney Int 81(2):190–195, 2012.